RxDoctor Payments Data

Coka Yip, NP

Family · Saint Clair Shores, MINPI 1295915908

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,780 of the $15,841 with a category attached, or 61.7%. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 96.9% of it on its own, with 6 other manufacturers making up the rest. Among family clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,841in general payments, 2019–2025

Across 56 payments — averaging $282.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$15K
  • Vibrant Gastro, Inc.$200
  • Sanofi$162
  • Aimmune Therapeutics, Inc.$42
  • Ardelyx, Inc.$40
  • Phathom Pharmaceuticals, Inc.$29
  • plus $22 from 1 others

What the payments were for

  • Consulting fees$9,78062%
  • Travel & lodging$4,32427%
  • Food & beverage$1,73711%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,841 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$8,741
Medicare patients
50
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin58$143,935
MotegrityPrucalopride Succinate171$141,505
LinzessLinaclotide39$32,862
TrulancePlecanatide33$28,752
IbsrelaTenapanor Hcl15$27,566
MovantikNaloxegol Oxalate33$18,904
CreonLipase/Protease/Amylase13$15,103
Lubiprostone39$8,638
Esomeprazole Magnesium37$4,161
ErythromycinErythromycin Base35$3,660
Sucralfate15$3,162
Rabeprazole Sodium13$1,458
Pyridostigmine Bromide18$1,448
Famotidine53$1,156
Ondansetron OdtOndansetron17$836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$15,345$172,68791 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$22$141,505171 claims
Ardelyx, Inc.Ibsrela$40$27,56615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Saint Clair Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →